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Historically, the treatment algorithm applied to non-small cell lung cancer (NSCLC) was the
same for all histologic subtypes. However, recent advances in our understanding of the
molecular profiles of squamous and non-squamous NSCLC have changed this perspective.
Histologic subtype and the presence of specific molecular abnormalities have predictive
value for response to and toxicity from therapy, as well as overall survival. For patients
with squamous NSCLC, a platinum agent plus gemcitabine, or paclitaxel is recommended
as first-line therapy. The role of epidermal growth factor receptor monoclonal antibodies is
uncertain. Maintenance therapy is not widely recommended, although data exist for the
use of erlotinib. The standard recommendation for second-line therapy is docetaxel and
erlotinib should be considered as second or third-line therapy. There is ongoing research
identifying molecular targets in squamous NSCLC and many agents are in early phase
clinical trials. Immunotherapeutic approaches targeting programed death-1 receptor and
its ligand (PD-L1) appear promising.
Keywords: non-small cell lung cancer, squamous cancer, molecular abnormalities, chemotherapy, EGFR inhibitors,
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INTRODUCTION
Historically, one simplified management algorithm was applied
to all patients with non-small cell lung cancer (NSCLC). A plat-
inum agent combined with paclitaxel, docetaxel, vinorelbine, or
gemcitabine was recommended for first-line chemotherapy (1,
2). Second-line chemotherapy at the time of disease progression
could include docetaxel (3, 4), or pemetrexed (5) and erlotinib was
recommended as second/third-line therapy (6). There was no evi-
dence that histologic subtype of NSCLC impacted on the response
to, or survival gained from chemotherapy (7).
However, important differences exist between the major sub-
types of NSCLC, which have prognostic and predictive value.
There is evidence from some trials, that patients with squamous
histology have worse overall survival (OS) than patients with
adenocarcinoma (8). Additionally, qualitative interactions exist
between histology and the efficacy of some treatments (9). Dif-
ferences also exist in the molecular profile of squamous and non-
squamous NSCLC (10). Mutations of the Epidermal Growth Factor
Receptor (EGFR), or Kirsten Rat Sarcoma (K-RAS) genes are rare in
squamous cancers (10). However,EGFR protein overexpression,or
increased gene copy number occur commonly. Differences exist in
the expression of thymidylate synthase (TS) (11). Higher messen-
ger RNA (mRNA) and protein levels for TS are seen in squamous
cancers compared to non-squamous cancers, although there is no
direct clinical correlation between levels of TS mRNA and mea-
sures of response to treatment. Nevertheless, separate treatment
algorithms for squamous cancers have evolved. In this review, we
summarize the approach to the management of squamous NSCLC.
FIRST-LINE THERAPY FOR SQUAMOUS CANCERS
Randomized trials in the 1980s demonstrated that chemother-
apy improved OS as well as quality of life (12). These initial
studies of platinum-based chemotherapy did not observe any
differential response, or survival, based on histologic subtype.
Multiple subsequent studies comparing various platinum-based
chemotherapy regimens demonstrated similar response rates and
OS (1, 2, 13). A retrospective review by the Southwest Oncology
Group (SWOG), of systemic therapy trials of anti-microtubule
agents, also showed no differential effect in outcomes according to
histologic subtype (7).
More recent data demonstrate that histologic subtype is pre-
dictive of a differential response rate, OS, or toxicity profile from
certain systemic therapies (9, 14, 15). The JMDB trial randomized
1725 patients with NSCLC (all histologic subtypes), to six cycles
of first-line chemotherapy with cisplatin and gemcitabine, or cis-
platin and pemetrexed (16). The primary outcome for the trial
showed that cisplatin and pemetrexed was non-inferior to cisplatin
and gemcitabine (median OS 10.3 months for both arms, HR 0.94,
95% CI 0.84–1.05). A planned sub-group analysis demonstrated
evidence of a qualitative interaction between treatment effect and
histology (interaction p= 0.0011). OS was significantly improved
for patients with non-squamous histology randomized to cis-
platin and pemetrexed, versus cisplatin and gemcitabine (11.8 vs.
10.4 months, HR 0.81, 95% CI 0.70–0.94). However, in patients
with squamous cancer, OS was significantly worse for patients
randomized to cisplatin and pemetrexed (9.4 vs. 10.8 months, HR
1.23, 95% CI 1.0–1.53).
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Similar evidence of an interaction between histology and treat-
ment efficacy for pemetrexed was observed in the JMEN trial
evaluating maintenance therapy with pemetrexed, following four
cycles of platinum-based chemotherapy (17). The improvement
in progression free survival (PFS) from maintenance pemetrexed
was significantly greater in patients with non-squamous histol-
ogy than squamous histology (HR 0.44, 95% CI 0.36–0.55 vs.
HR 0.69, 95% CI 0.49–0.98; interaction p= 0.036). Similarly the
observed improvement in OS was limited to patients with non-
squamous histology (HR 0.70, 95% CI 0.56–0.88 vs. HR 1.07, 95%
CI 0.77–1.50, interaction p= 0.033). A second large randomized
trial of maintenance therapy following first-line platinum-based
chemotherapy evaluated erlotinib (18). The SATURN trial, which
included approximately 40% of patients with squamous cancers,
showed a modest improvement in OS for patients randomized to
maintenance erlotinib compared with placebo (12 vs. 11 months,
HR 0.81, 95% CI 0.70–0.95). There was no evidence of any inter-
action between treatment and histology (squamous HR 0.86, 95%
CI 0.68–1.10, adenocarcinoma HR 0.77, 95% CI 0.61–0.97).
Several trials have evaluated gemcitabine as maintenance ther-
apy (19–21). Brodowicz et al. (20) randomized patients to main-
tenance gemcitabine or placebo, after four cycles of cisplatin and
gemcitabine. There was a significant improvement in TTP, but
no significant improvement in OS. In contrast, Belani et al. (19)
found no improvement in PFS or OS, for continuation mainte-
nance gemcitabine. Data were not analyzed according to histology.
Lastly, the IFCT-0502 trial randomized patients to gemcitabine,
erlotinib, or observation, after first-line cisplatin and gemcitabine
(21). Improvements in PFS were observed for patients randomized
to both gemcitabine and erlotinib, compared with observation, but
no differences were observed in OS. For patients randomized to
gemcitabine, the improvement in PFS seemed less for patients with
adenocarcinoma than other histologies (HR 0.98 vs. 0.79). There
is insufficient data to recommend maintenance gemcitabine in this
setting.
The selection of first-line therapy for NSCLC is also influ-
enced by differing toxicity profiles between the histologic subtypes.
Major hemoptysis was observed in the randomized phase II trial
evaluating the addition of bevacizumab to first-line carboplatin
and paclitaxel (14). There was an excess risk of life threaten-
ing hemoptysis in patients with squamous cancers and these
patients were excluded from subsequent trials of bevacizumab in
NSCLC. More recently, an open-label single-arm phase II study,
the BRIDGE trial, evaluated delaying bevacizumab until after the
third cycle of carboplatin and paclitaxel, in 31 patients with squa-
mous NSCLC (22). Severe pulmonary hemorrhage was observed
in 1 patient and grade 3 toxicities occurred in 9 of 31 patients over-
all. The authors conclude that bevacizumab remains experimental
therapy in patients with squamous NSCLC.
Additional trials evaluating other targeted agents have also
shown worse outcomes for patients with squamous NSCLC. The
ESCAPE trial randomized 926 patients with advanced NSCLC (all
histologies) to carboplatin, paclitaxel with or without sorafenib
(15). The study was discontinued early following an interim analy-
sis demonstrating futility. In the final analysis of this trial, patients
with squamous histology (n= 223) randomized to chemother-
apy plus sorafenib had worse OS than patients randomized to
chemotherapy alone (8.9 vs. 13.6 months, 95% CI 1.22–2.81), as
well as lower PFS (4.3 vs. 5.8 months, HR 1.31 95% CI 0.94–1.83).
However, for some agents, squamous histology appears to pre-
dict better outcomes from treatment. The BMS-099 phase III trial
randomized patients with advanced NSCLC to carboplatin and
paclitaxel or docetaxel, with or without cetuximab (23). Although
the response rate was better for patients randomized to chemother-
apy plus cetuximab (25.7 vs. 17.2%, p= 0.007), there was no
difference in PFS, or OS. There was a trend to greater benefit from
the addition of cetuximab to chemotherapy, in patients with squa-
mous NSCLC (HR 0.7, 95% CI 0.47–1.05) compared to patients
with adenocarcinoma (HR 0.9, 95% CI 0.71–1.14). A second phase
III trial, the FLEX trial, evaluated the addition of cetuximab to cis-
platin and vinorelbine chemotherapy in patients with advanced
NSCLC demonstrating EGFR expression on immunohistochem-
istry (IHC) (24). There was a modest improvement in OS for
patients randomized to chemotherapy plus cetuximab compared
with chemotherapy alone (11.3 vs. 10.1 months, HR 0.871, 95%
CI 0.762–0.996). There was a trend for greater benefit in patients
with squamous histology (HR 0.8, 95% CI 0.64–1.0) compared
to patients with adenocarcinoma (HR 0.94, 95% CI 0.77–1.15).
However, a meta-analysis of four trials of first-line cetuximab plus
chemotherapy in advanced NSCLC did not find clear evidence for
a differential effect of treatment according to histology (25).
There does appear to be a differential effect of treatment accord-
ing to histology for necitumumab, a second EGFR monoclonal
antibody. The INSPIRE trial evaluating the addition of necitu-
mumab to cisplatin and pemetrexed in non-squamous NSCLC
patients, was stopped early because of an increased risk of throm-
boembolic complications in the necitumumab arm (26). However,
a press release from Eli Lilly earlier in 2014, announced that
a similar trial in patients with squamous NSCLC, had demon-
strated improved OS for patients receiving cisplatin plus gemc-
itabine in combination with necitumumab, compared with cis-
platin and gemcitabine alone. These data should be available
during 2014.
The available data support adopting a different algorithm for
first-line therapy of patients with squamous NSCLC compared
with non-squamous histology. While cisplatin and pemetrexed
appears to be the preferred chemotherapy in patients with non-
squamous NSCLC, pemetrexed appears to be an ineffective drug
in patients with squamous cancers. The JMBD trial did show that
cisplatin and gemcitabine was superior chemotherapy in patients
with squamous cancers (16). However, other trials, such as ECOG
1594, have demonstrated similar survival to cisplatin and gemc-
itabine from alternate chemotherapy regimens such as carboplatin
and paclitaxel (2). Either one of these regimens would be an appro-
priate choice for first-line chemotherapy in patients with advanced
squamous NSCLC. The role of EGFR monoclonal antibodies is
somewhat uncertain. The benefit from cetuximab is very modest
and there are additional toxicities. Therefore, it has not been widely
implemented into first-line treatments. Data on necitumumab will
need to be examined more closely once it is presented, in order to
determine whether it should be incorporated into routine man-
agement of patients with squamous NSCLC. Finally, maintenance
options in squamous NSCLC are limited. Pemetrexed is ineffective
as maintenance therapy for patients with squamous cancers and
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the benefit of erlotinib is modest. Therefore, maintenance therapy
in this population is not routinely employed.
SECOND-LINE CHEMOTHERAPY FOR SQUAMOUS CANCERS
Second-line chemotherapy for NSCLC has been widely adopted
since publication of two randomized trials in 2000 (3, 4). The
TAX 317 trial randomized patients to docetaxel or best supportive
care following first-line platinum chemotherapy (4), whereas the
TAX 320 trial randomized patients to docetaxel vs. either vinorel-
bine, or ifosfamide (3). Both trials showed modest, but significant
improvements in OS and the TAX 317 trial also demonstrated
improvement in lung cancer related symptoms (27). A further
trial compared second-line therapy with docetaxel to pemetrexed
(JMEI) (5). This trial demonstrated that pemetrexed was non-
inferior to docetaxel (median OS 8.3 vs. 7.9 months, HR 0.99,
95% CI 0.83–1.2). Secondary outcomes including response rate,
time to progression, and duration of response were also simi-
lar between the two groups. Therefore, pemetrexed and docetaxel
were both established as options for second-line chemotherapy for
NSCLC.
A retrospective analysis was subsequently undertaken of the
JMEI trial to look for an interaction between treatment effect and
histology (8, 9). Similar to data in the first-line setting, there was
a qualitative interaction between histology and treatment effect.
Patients with non-squamous histology treated with pemetrexed,
had significantly longer survival (9.3 vs. 8.0 m, HR 0.78 95% CI
0.60–1.02, interaction p= 0.04). On the other hand, patients with
squamous histology who received pemetrexed had inferior sur-
vival (6.2 vs. 7.4 months, HR 1.56 95% CI 1.08–2.26). This analysis
primarily showed that patients with squamous NSCLC treated
with pemetrexed had an inferior outcome.
These data support a differential approach to second-line
chemotherapy according to histology. Docetaxel is recommended
as second-line chemotherapy in patients with squamous type
NSCLC, whereas pemetrexed is recommended for patients with
non-squamous NSCLC. However, due to the adoption of peme-
trexed in the first-line setting, docetaxel remains an option
for second-line chemotherapy, in patients with non-squamous
histology.
ERLOTINIB THERAPY IN PATIENTS WITH SQUAMOUS
CANCERS
Many patients with advanced NSCLC are still candidates for fur-
ther systemic therapy, at the time of progression on second-line
chemotherapy. There is little evidence though, to support the
use of a third-line of chemotherapy. However, the results of the
BR21 trial of erlotinib vs. best supportive care support the use of
erlotinib as second or third-line therapy (6). This trial enrolled
731 patients, including patients with poor performance status
(ECOG 2 and 3), who had previously received one or two lines
of chemotherapy (49% received two prior lines of chemother-
apy). The trial demonstrated that erlotinib significantly improved
PFS (2.2 vs. 1.8 months, HR 0.61, 95% CI 0.51–0.74) and OS (6.7
vs. 4.7 months, HR 0.70, 95% CI 0.58–0.85). In addition, time to
deterioration in cough, dyspnea, and pain were all significantly
improved for patients randomized to erlotinib. The benefit of
erlotinib was similar in both second and third-line settings.
Since publication of the BR21 trial, there has been a con-
siderable body of evidence demonstrating that the presence of
activating mutations of the EGFR gene are strongly predictive of
benefit from an EGFR tyrosine kinase inhibitor (TKI) (28). It has
been argued that the benefit of an EGFR TKI is limited to such
patients with an EGFR mutation. Given that EGFR mutations are
rare in patients with squamous cancers, it has also been argued
that EGFR TKIs are ineffective in this group of patients as well.
However, the data from both BR21 and the SATURN trial of main-
tenance erlotinib (18), demonstrate that patients who are EGFR
wild type also benefit from EGFR TKIs, although the magnitude
of benefit may be smaller. Similarly, available data do not support
the contention that patients with squamous cancers fail to benefit
from an EGFR TKI. In the BR21 trial, 31% of patients had squa-
mous histology. The magnitude of benefit from erlotinib appeared
similar in patients with squamous cancers (HR 0.8, 95% CI 0.6–
1.0) and patients with adenocarcinoma (HR 0.7, 95% CI 0.6–0.9).
Therefore, erlotinib should be considered as a second or third-line
option for treatment in patients with squamous NSCLC. To date
no other agents have be shown to improve survival in this setting.
FUTURE DIRECTIONS
The molecular profile of adenocarcinomas of the lung has been
well described (29). Common mutations in lung adenocarcinoma
include K-RAS, EGFR, as well as translocations of the Anaplas-
tic Lymphoma Kinase (ALK) gene. However, there has been less
research characterizing molecular abnormalities in lung cancer
patients with squamous tumors. The cancer genome atlas (TCGA)
network published data on genomic and epigenetic analysis of
178 squamous NSCLC patients from across the world (30). The
data suggest squamous NSCLC’s are genetically complex tumors. A
high proportion of squamous cancers (171 of 178) contain one or
more mutations in tyrosine kinases, serine/threonine kinases,PI3K
catalytic and regulatory subunits, nuclear hormone receptors, G
protein-coupled receptors, proteases, and tyrosine phosphatases.
Common molecular abnormalities include mutations and ampli-
fication of fibroblast growth factor receptor gene (FGFR), muta-
tions of phosphatidylinositol 3-kinase, catalytic subunit alpha gene
(PIK3CA), phosphatase and tensin homolog gene (PTEN), discoid
domain receptor 2 gene (DDR2), BRAF, as well as EGFR ampli-
fication (31). This would suggest that squamous cancers have
a different molecular phenotype, hence the need for a separate
treatment algorithm. Multiple clinical trials are ongoing evalu-
ating agents targeting these molecular abnormalities, which will
further refine the treatment algorithm in squamous NSCLC.
Immune based therapies also appear to be gaining momentum
in NSCLC. There is considerable interest in immune checkpoint
regulation in NSCLC. In particular, therapy directed toward the
programed death-1 receptor (PD-1), or its ligand PD-L1 has
shown considerable promise in early phase clinical trials. Phase
I trials of several PD-1 receptor monoclonal antibodies, includ-
ing nivolumab (32), MK-3475 (33), as well as the PD-L1 antibody
MPDL-3280A (34) have all shown evidence of anti-tumor activ-
ity in heavily treated NSCLC patients. Approximately 20% of
patients have shown objective tumor responses and many of these
responses have been durable beyond 1 year. Response rates of 60–
70% were observed in patients with tumors expressing PD-L1,
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although there is a need to develop valid and reliable methods
of assessment of this. Of note, the response rates among patients
with squamous cancers appear to be higher than response rates
in patients with adenocarcinoma, although it is unclear whether
histology or some underlying molecular difference may account
for these findings. Data also exist for the CTLA-4 antibody, ipil-
imumab. A randomized phase II trial of chemotherapy with six
cycles of carboplatin and paclitaxel, chemotherapy plus ipili-
mumab in cycles one to four (concurrent) and chemotherapy
plus ipilimumab in cycles three to six (phased). Patients ran-
domized to carboplatin, paclitaxel, and phased ipilimumab had
improved PFS compared with the control arm (HR 0.72, 95% CI
0.50–1.06, p= 0.05). These data require confirmation in phase III
trials. The data suggest patients with squamous cancers may have
more benefit from the addition of ipilimumab (HR 0.55, 95% CI
0.27–1.12) than patients with non-squamous cancers (HR 0.81,
95% CI 0.53–1.26).
CONCLUSION
It is clear that a different treatment algorithm has emerged for
patients with squamous NSCLC. In the first-line setting platinum
doublets involving gemcitabine, or potentially paclitaxel should
be considered. The role of EGFR monoclonal antibodies such as
cetuximab and necitumumab, require further clarification. Treat-
ment options beyond progression of first-line therapy include
docetaxel and erlotinib. Multiple trials are currently examining
new therapies targeting the common molecular abnormalities
observed in squamous lung cancers.
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